Clinical Value of Tranexamic Acid Combined with Total Knee Arthroplasty in the Treatment of Knee Osteoarthritis

Abstract

This paper aims to explore the clinical value of tranexamic acid combined with total knee arthroplasty (TKA) in patients with knee osteoarthritis (KOA). The research period was from March 2020 to December 2022. A total of 50 samples of KOA patients were selected and divided into the study group (n = 25) and the control group (n = 25) by lottery method of medical record envelopes. The patients in the control group were treated with TKA, and the patients in the study group were treated with tranexamic acid combined with TKA. The surgery-related indicators, visual analogue pain score (VAS), inflammatory factor levels, motor function scores, and incidence of complications were compared between the two groups. The intraoperative blood loss in the study group was lower than that in the control group (P < 0.05), and there was no significant difference in postoperative hospital stay between the two groups (P > 0.05). The postoperative VAS scores in the study group were lower than those in the control group (P < 0.05), while the postoperative inflammatory factor levels of the study group were lower than those of the control group (P < 0.05). The postoperative motor function scores of the study group were higher than those of the control group (P < 0.05), and the incidence of complications in the study group was lower than that in the control group (P < 0.05). The treatment of KOA patients with tranexamic acid combined with TKA can reduce intraoperative blood loss, relieve pain, reduce the level of inflammatory factors, improve postoperative motor function, and reduce the incidence of complications, which can be widely applied in clinical practice.